NeuroXNet: Creating A Novel Deep Learning Architecture that Diagnoses Neurological Disorders, Finds New Blood Biomarkers, and Assesses Surgical, Drugs, and Radiation Treatment Plans Using Medical Imaging and Genomic Data

Vaibhav Mishra¹

West Laurens High School, 3692 GA-257, Dexter, GA 31019

Abstract

Neurodegenerative diseases and cancerous brain tumors cause millions of patients worldwide to be fatally ill and face cognitive impairment each year. Current diagnosis and treatment of these neurological conditions take many days, are sometimes inaccurate, and use invasive approaches that could endanger the patient's life. Thus, this study's purpose is the creation of a novel deep learning model called NeuroXNet, which uses MRI images and genomic data to diagnose both neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and Mild Cognitive Impairment as well as cancerous brain tumors, including glioma, meningioma, and pituitary tumors. Moreover, the model helps find novel blood biomarkers of differentially expressed genes to aid in diagnosing the six neurological conditions. Furthermore, the model uses patient genomic data to give additional recommendations for treatment plans that include various treatment approaches, including surgical, radiation, and drugs for higher patient survival for each class of the disease. The NeuroXNet model achieves a training accuracy of 99.70%, a validation accuracy of 100%, and a test accuracy of 94.71% in multi-class classification of the six diseases and normal patients. Thus, NeuroXNet reduces the chances of misdiagnosis, helps give the best treatment options, and does so in a time/cost-efficient manner. Moreover, NeuroXNet efficiently diagnoses diseases and recommends treatment plans based on patient data using relatively few parameters causing it to be more cost and time-efficient in providing non-invasive approaches to diagnosis and treatment for neurological disorders than current procedures.

Keywords: Alzheimer's Disease; Parkinson's Disease; Mild Cognitive Impairment (MCI); Brain Tumors; Medical Imaging; Neuroscience; Blood Biomarkers; Genomics

¹Corresponding author: vaibhavrichmishra@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

I. Introduction

1.1 Background

Neurological disorders continue to affect millions of people worldwide, with diseases leading to loss of cognitive function, a decline in memory, and even death. These diseases contribute to nearly a trillion dollars of healthcare spending and drastically change the lives of those affected. With the advent of new medical imaging and computational techniques, it has become possible to use large amounts of imaging data to build and train deep learning models that can diagnose many diseases with high accuracy rates using clinical tests and medical imaging tests like MRI. Some of the most common neurodegenerative disorders include Alzheimer's disease, Parkinson's disease, and Mild Cognitive Impairment. In the United States, approximately 6.2 million people are affected by AD [6], 1 million people are affected with PD [7], and 11 million people are affected with MCI [8].

Alzheimer's Disease (AD) is the most common neurodegenerative disease that starts with MCI like symptoms of memory loss and cognitive decline and later evolves to damage neurons responsible for carrying out essential functions affecting everyday life. Eventually, AD can result in the death of a patient. Some possible causes of AD include beta-amyloid plaques that form outside the neurons and tau tangles inside neurons, which have been observed inside several AD patients [6]. MRI images can diagnose AD earlier by locating critical parts of the brain that signal a higher possibility of AD. Some of the primary areas used to diagnose AD in the brain are the hippocampus and the parietal lobes. However, in patients with AD, the MRI will clearly show a decrease in the size of the hippocampus signaling a higher probability of AD. The parietal lobe is also a signal that radiologists look for in diagnosing AD through MRIs. The parietal lobe is responsible for sensory information and visual processing in our bodies. A size reduction in a patient's parietal lobe also signals a chance of AD in a patient. [18] Therefore, MRIs must be adequately interpreted and used to give an early diagnosis of patients to prevent AD from progressing. Mild Cognitive Impairment (MCI) is a neurological condition with symptoms that show loss of certain cognitive functions like memory or the ability to speak. MCI can convert to AD or other types of dementia over a few years, remain stabilized as MCI, or revert to a normal functioning brain. The most common treatment of MCI is Aducanumab, a drug used to treat AD. [8] One major problem of diagnosis of MCI is that MCI can be similar in symptoms to normal cognitive decline due to old age in many people, which causes many patients to ignore the signs and leave MCI untreated. This is harmful as MCI can later develop into AD over time. Therefore, it is crucial to diagnose and treat MCI in its early stages to avoid more cognitive loss in patients.

Parkinson's Disease (PD) is a neurological disease that primarily damages the motor neurons disturbing a patient's movement ability. PD usually results in patients having worse conditions over more extended periods. However, PD can be treated with certain medications like Carbidopa-levodopa [10]. MRIs can help detect specific abnormalities to brain structures that signal PD in PD patients. Particularly in PD, there are significant changes seen in the right parietal cortex, the putamen, and brain structures responsible for motor actions like the mesencephalic locomotor region. The right parietal lobe is chiefly responsible for various functions of the body, including taste, touch, and the somatic sensory cortex within it. The putamen has the function of controlling movement, and as such, these areas are critical for PD diagnosis [19].

Glioma tumors are located in the central nervous system, and various glial cells are found throughout the peripheral nervous system, including astrocytes, oligodendrocytes, and microglia. Glioma tumors include glioblastoma multiforme, astrocytoma, and oligodendroglioma. Oligodendroglioma can occur in either the temporal or frontal lobes and cause seizures and motor inability. This study focuses on more lethal kinds of brain tumors, including anaplastic astrocytoma (which appears more commonly in the cerebral hemisphere) and glioblastoma multiforme (which starts in the cerebrum in astrocyte cells) [26]. Pituitary tumors primarily occur in the anterior portions of the pituitary gland. Pituitary tumors cause vertigo, fatigue, and problems with visual perception [26]. Pituitary tumors are generally treated through surgery using transsphenoidal resection [26]. Meningioma tumors occur on the meninges of the brain and can cause vision problems as well as seizures [26].

1.2 Previous Literature

Through the usefulness of large amounts of data and advancements in medical imaging research, it has become possible to diagnose and even treat patients with diseases in various fields of medicine. A large amount of medical imaging research using MRI data has been used to classify AD from normal patients. For instance, Al- Khazaie et al. [4] developed a new model, AlzNet, which achieved an accuracy of 99.30% in diagnosing AD from normal using 2D MRI slices. One of the highest accuracies was achieved in AD diagnosis using machine learning models. Another paper [11] trained a CNN model to classify AD, normal, and MCI patients using 3D MRI with an accuracy of 52.3%.

Medical imaging research has also been extended into PD classification from normal patients. Multiple models have been developed that incorporate a machine learning approach to classify PD from MRI imaging. A research team led by Long [1] developed a model in which accuracy of 86.96% was achieved in classifying and diagnosing PD patients from normal patients. In [56], computational tools identify novel blood biomarkers in PD patients using gene ontology analysis and protein interactions.

However, relatively few machine learning models have performed multiclass diagnosis in neurological disorders. A multiclass approach to classifying multiple neurodegenerative diseases was studied in very few papers, notably in [14], where AD, PD, and CN were classified with an accuracy of 90% for AD, 90% for control from ADNI, 89% for control from PPMI, and 90% for PD using transfer learning on the VGG19 model which performed the best out of the ResNet 50, Inception Net, and VGG16 model which were also tested in the paper and in another article by Tong et al. [15], where a five-class model was proposed that achieved a 75.2% that classified AD and other dementia-like diseases using the RUSBoost algorithm. Even in these studies, the model was limited to classifying only neurodegenerative diseases in lesser than five classes. Therefore, this study aims to solve the problem of multiclass diagnosis and treatment of neurological disorders.

1.3 Purpose of Study

This study proposes a novel deep learning architecture, NeuroXNet, which performs multiclass diagnosis of AD, PD, MCI, glioma, meningioma, pituitary, and normal patients. In addition, NeuroXNet generates recommendations for treatment based on disease classification from its convolutional neural network (CNN) model combined with the patient's genomic and clinical data. These recommendations include treatment plans for surgery, radiation, or drug therapy. This is the first CNN model which creates a novel architecture to study multiclass diagnosis instead of relying on previously built models like ResNet50 or VGG16. Furthermore, this model discovers new blood biomarkers using genomic data to further aid in diagnosing neurological conditions and reducing the chance of misdiagnosis. These genes can also be further studied to find possible targets for treatment research. Moreover, this model is the first that combines diagnosis with treatment plans for neurological disorders. Therefore, this model has great potential to be used in neurological medicine and provide a low-cost, efficient, and quick solution to patients worldwide.

II. Materials and Methods

2.1 Data Acquisition and Description for MRI Classifier

Data of AD and MCI patients used in the paper was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a free open source database (adni.loni.usc.edu), and data for the PD and normal patients was obtained from the Parkinson's Progression Markers Initiative (PPMI) database (ppmi-info.org). Data for MRI of patients with glioma, meningioma, and pituitary tumors were acquired from Kaggle's Brain Tumor Dataset [22]. For each of the seven AD, PD, MCI, Pituitary Tumor, Glioma Tumor, Meningioma Tumors, and Normal Patients, 1000 Brain MRI images were collected NIFTI format

from the respective databases for a total of 7000 images. All the MRIs were T1-weighted and equally distributed to reduce model bias. These images were then converted to png format using the MRICro tool. The images were split into training/validation/test folders using a 70%/30%/10% ratio. Table 1 shows the number of patient MRIs that were split into Training, Validation, and Test sets for each disease class.

Table 1: Data Split Into Training, Validation, and Test Sets				
	Training Set	Validation Set	Test Set	Total
Alzheimer's Disease	700	300	100	1000
Parkinson's Disease	700	300	100	1000
Mild Cognitive Impairment	700	300	100	1000
Glioma Tumor	700	300	100	1000
Meningioma Tumor	700	300	100	1000
Pituitary Tumor	700	300	100	1000
Normal Control	700	300	100	1000
Total	4900	2100	700	7000

Table 1: Number of Patients per Data Set Folder

The demographic data including age and gender for the neurodegenerative classes is shown below in Table 2:

Table 2: Demographic Data of Neurodegenerative Disease Classes					
	Number of Subjects	Number of Male Subjects	Number of Female Subjects	Average Age	Range of Age
Alzheimer's Disease	1000	307	693	77.73±5.51	[72,87]
Parkinson's Disease	1000	617	383	60.39±8.43	[39,76]
Mild Cognitive Impairment	1000	462	538	75.74±8.98	[58,92]
Normal Control	1000	318	682	60.93±10.89	[31,81]

Note: Average Age represents age±standard deviation and range of age represents [min,max].

Table 2: Demographic Data for Neurodegenerative Diseases

2.2 Data Preprocessing for Diagnosis

After being split into their respective folder, each MRI image was normalized by rescaling the size of each image. Then, data augmentation was applied, including shearing, zooming, and flipping the data to decrease overfitting and improve the model's overall accuracy. The data was preprocessed to reduce the amount of data bias the model gains and helps make the model regularize to fit all ranges of MRI images.

2.3 Deep Learning Models Overview

Convolutional Neural Networks (CNNs) are a class of deep neural networks part of supervised machine learning that are most widely used for visual image processing, including medical imaging. CNN's use multiple layers to take input images, find patterns within them, and learn from certain features

within the pictures. They then use the learned weights and biases to output the image's class. A convolutional layer is the centerpiece of the NeuroXNet model, which uses a set of weights and biases (also called factors) that learns over time.

2.4 Identification of Novel Biomarkers

Identifying biomarkers from blood, tissue, or another type of body cell for early detection of neurological diseases was one of the main focuses of this study. Blood biomarkers are analyzed with microarrays to gather data on gene expression for thousands of genes and subsequently used as a non-invasive neurological test for diagnosis and research in finding new treatments. This study utilized genomic datasets from Gene Expression Omnibus. The data used in this study consisted of the series GSE74385 [46, 47] for meningioma tumor classification, GSE31095 [48] for glioma tumors, GSE4488 [49] for pituitary tumors, GSE63063 [50] for MCI classification, GSE6613 [51, 52] for PD classification, and GSE4226 [53, 54] for AD classification. Each gene expression study was used to find differentially expressed genes that would serve as blood biomarkers for diagnosing the specific neurological disorder. The NeuroXNet model used to classify patients by genomic data.

Using GEO2R, the patients were split into two groups for each series number, with one group consisting of the specific disease class and the other group with normal patients. Then, all differentially expressed genes with a p-value of less than 0.05 were used to generate a protein interaction network using the STRING tool. The protein interaction network was then used to identify hub genes with a high number of nodes using the Cytoscape tool. The hub genes are the differentially expressed genes that are over-expressed in patients with certain neurological conditions and are potential biomarkers for the disease. These hub genes were sorted by degree (number of nodes connected to) and used for gene ontology analysis using the PANTHER tool, which gave the false positive rate, fold enrichment, and p-values for the specific genes present in biological, molecular, and cellular processes.

The fold change represents the ratio of the average gene expression in the experimental group vs. the control group. This study focused on the over-expressed genes with fold change values greater than 1.

2.5 NeuroXNet Model Description

NeuroXNet is the novel CNN model created in this study that uses patient MRI data and genomic data to diagnose and give treatment recommendations to patients, including surgical, radiation, and drug treatments to improve patient survivability. First, the model inputs MRI images, preprocesses them and sends them to the NeuroXNet Model. The model uses pre-trained weights to classify the patient's MRI as AD, PD, MCI, glioma tumor, meningioma tumor, pituitary tumor, or normal. Next, genomic data of the

patient is entered in as a secondary input and used to diagnose the patient again to ensure an accurate diagnosis. The model diagnoses patients using its pre-trained algorithm from blood biomarkers which it found beforehand. The classification information is then passed through the treatment tool of the NeuroXNet model, which matches the classified disease to its best treatment plan taking into account the susceptibility of the disease to drug treatments, radiation treatments, or surgical treatments starting from non-invasive options first that provide the most minor side effects to the patient and eliminating options that have low rates of survival based on patient's genomic data. The process is shown in Figure 1 below:

Figure 1: NeuroXNet Model Workflow Analysis

The next three sections detail the kind of algorithmic process that the NeuroXNet model goes through in suggesting treatment procedures for patients.

2.6 Surgical Treatment Procedures

For surgical procedures, NeuroXNet focuses on only widely used methods and can cause significant improvements to patient health. The model makes recommendations based on the diagnosed disease input from the result of its CNN model.

For patients diagnosed with PD, the model considers only the two main surgical methods used by surgeons: Deep Brain Stimulation (DBS) and Duopa. DBS is a surgical procedure that involves placing electrodes into the brain with an impulse generator battery that is connected to a wire that passes through the head and shoulder. DBS delivers electrical stimulation to the subthalamic nucleus and the globus pallidus internus, which control movements that cause tremors to reduce PD symptoms [28]. DBS is used for patients that are in the early stages of PD and experience uncontrolled tremors [28].

For patients that are diagnosed with MCI, the NeuroXNet model consists of mainly one surgical treatment procedure: Transcutaneous Electrical Nerval Stimulation (TENS). TENS is a medical procedure that involves applying an electrical current to electrodes located on the skin in order to reduce pain in patients. TENS improves cognitive functioning, as well as counters, sleep disorders, and neural degeneration [30].

For patients that have pituitary tumors, the model either suggests a craniotomy or an endoscopic transnasal transsphenoidal approach [31]. A craniotomy is performed by making an incision on the scalp, after which a portion of the skull is removed. Then, as much of the tumor that can be removed without harming healthy brain tissue is taken out. Next, the skull part is replaced, and the incision is closed [32]. An endoscopic transnasal transsphenoidal approach involves removing the tumor through the nasal pathway [31]. The model suggests craniotomy only if the tumor is greater than or equal to 10mm in diameter size. Otherwise, it offers an endoscopic transnasal transsphenoidal approach.

For diagnosis as a meningioma tumor, if the tumor is found in the ventricular chambers, neuroendoscopic surgery is recommended by the model. Otherwise, if the tumor is large (10mm or more in diameter size), a craniotomy is suggested. If the tumor is small, then an endoscopic endonasal approach is recommended. Intraventricular infusion involves delivering antibodies into the brain to provide immunization against amyloid-beta peptides in the amyloid plaques that are found in AD patients [33]. Gene therapy consists in injecting brain-derived neurotrophic factors (BDNF) into the CNS to increase neuronal growth to reverse AD progression [34]. Cerebrospinal fluid shunting involves draining CSF from ventricles of the brain. This causes fresh CSF to form, which are free from tau proteins (a major cause of AD). CSF shunting is seen to decrease tau proteins by 60% in AD patient brains [35].

Table 5: Surgical Treatment Summary for NeuroXNet		
	Determining Factor	Result
PD	Early Stages of PD	Deep Brain Stimulation
	Late Stages of PD	Duopa
MCI	Patient Needs Pain Control	Transcutaneous Electrical Nerval Stimulation (TENS)
	Does Not Need Pain Control	Use Medicine or Alternative Approaches
Pituitary	Tumor grater than or equal to 10mm in diameter size	Craniotomy
	Tumor less than 10mm in diameter size	Endoscopic Transnasal Transsphenoidal Approach
Meningioma	Tumor found in ventricular chambers	Neuroendoscopic Surgery
	Tumor grater than or equal to 10mm in diameter size	Craniotomy
	Tumor less than 10mm in diameter size	Endoscopic Endonasal
Glioma	Tumor has caused build up of CSF	Shunt Placement
	Surgery Needed to Test Tumor Removal Effects	Brain Mapping and Awake Surgery
	Surgery Needed to Test Tumor Tissue	Surgical Biopsy
	Surgery Required to Remove Tumor Without Any Functionality Tests	Surgical Resection
AD	Patient Needs Pain Control	Transcutaneous Electrical Nerval Stimulation (TENS)
	Patient in Early Stages of AD	Cerebrospinal Fluid Shunting
	Patient in Moderate Stage of AD	Gene Therapy
	Patient in Late Stage of AD	Intraventricular Infusion

2.7 Radiation Treatment Procedures

Patients classified as having AD have been recorded to see vast improvements when exposed to low doses of ionizing radiation [42]. Advances in cognitive and motor functions were observed on AD patients exposed to the amounts of radiation [42]. Thus, NeuroXNet proposes low doses of ionizing radiation for patients who seek a non-invasive approach.

NeuroXNet recommends patients with meningioma tumors that have tumors near crucial brain structures IMRT. Otherwise, for large tumors, fractionated stereotactic radiotherapy is used. If the meningioma cannot be removed through the previous methods, then proton beam radiation is recommended to be used [44].

For patients with glioma tumors, there are two main types of radiation therapy that NeuroXNet recommends: IMRT and Image-Guided Radiation Therapy (IGRT). IGRT uses imaging software during treatment to adjust positions as needed. IMRT uses software to target radiation on the tumor and eliminate it directly. For tumors that are glioblastomic in nature, radiation therapy can be combined with the intake of temozolomide. Glioblastoma can also be treated by proton therapy [45]. NeuroXNet generates a treatment plan based on if the tumor is glioblastoma and if the patient's tumor would be removed better through real-time imaging or not.

Table 6: Radiation Treatment Summary for NeuroXNet		
	Determining Factor	Result
PD	Patient Needs Non-Invasive Approach	Stereotactic Radiosurgery
MCI	No Radiation Treatment Available	No Radiation Treatment Available
Pituitary	Brain Tumor is Near Sensitive Areas	Intensity-Modulated Radiation Therapy
	Brain Tumor Outside Sensitive Areas	Proton Beam Radiation or Stereotactic Radiotherapy
Meningioma	Tumor near Crucial Brain Structures	Stereotactic Radiotherapy
	Tumor Outside Crucial Brain Structures	Proton Beam Radiation
Glioma	Tumor does not need real-time imaging	Intensity-Modulated Radiation Therapy
	Tumor needs real-time imaging	Image-Guided Radiation Therapy
	Tumor is glioblastoma	Proton Radiation Therapy + Temozolomide
AD	Patient Needs Improvement in Cognitive and Motor Functions	Low Doses of Ionizing Radiation

2.8 Drug Treatment Procedures

For AD patients, one of the prime medical drugs used for treatment is Aducanumab which attacks beta-amyloid proteins to reduce amyloid plaque sizes, improving cognitive function and other AD-related symptoms [38]. Other drugs that may be used include cholinesterase inhibitors like Donepezil or Rivastigmine, which improves memory and thinking functions in the brain; glutamate regulators like memantine which will enhance overall cognitive functions; and orexin receptor antagonists with suvorexant to improve behavioral symptoms [38].

The most effective drug treatment plan for patients diagnosed with PD is using levodopa with carbidopa. Levodopa is a CNS agent converted to dopamine in the brain, helping ease PD symptoms as a lack of dopamine causes PD. Carbidopa is a decarboxylase inhibitor used with levodopa and stops levodopa from being converted into dopamine before it crosses the blood-brain barrier [36]. However, this combination of drugs does not work for some patients and causes dyskinesia. This is seen to be because of DNA methylation that changes the structure of the striatal methylome or causes methyl groups to be lost, causing Levodopa-induced dyskinesia [37].

The best option for meningioma tumors is to get surgical treatment to remove their tumors. However, drug treatment can also be used with limited efficiency for those unable to get surgical treatment. The most common drugs used to treat meningioma tumors include antibody proteins like Interferon, Bevacizumab, and Hydroxyurea which prevent the growth of cancerous cells and decrease blood flow to the tumor by providing support to the immune system [39].

One of the most effective drug treatments for glioma tumors is Temozolomide (TMZ), which reduces tumor size by fastening the DNA of the cancerous cells and preventing cell division. TMZ is

more effective than other drugs because it can pass through the blood-brain barrier and directly attack the cancerous tumor inside [23]. However, for patients with the O6-methylguanine methyltransferase (MGMT) protein over-expressed in glioma cells, TMZ could result in glioma cells becoming resistant and not being treated through medicine alone. This occurs because MGMT encodes a DNA repair enzyme which can cause the glioma cells to resist treatment with TMZ. TMZ treats both glioblastoma multiforme and anaplastic astrocytoma and is widely used with inhibitors of MGMT enzyme to counter any resistance that the cancerous cells build to the drug [24]. One of the most effective combinations of medications includes TMZ combined with MGMT-modified $\gamma\delta$ T cells, which effectively prevents tumor growth and immunizes tumors through NKG2D ligands [25].

Table 7: Drug Treatment Summary for NeuroXNet		
	Determining Factor	Result
PD	Patient Does Not Have DNA Methylation Occuring In Brain Cells	Levodopa+Carbidopa
	Patient Has DNA Methylation Occuring In Brain Cells	Levodopa+Carbidopa+Drugs used to prevent Levodopa-Induced Dyskinesia
MCI	No Medication Treatment Available	No Medication Treatment Available
Pituitary	Pituitary tumor secretes excess cortisol	Ketoconazole
	Pituitary tumor secretes excess growth hormone	Pegvisomant
	Pituitary tumor secretes excess prolactin	Bromocriptine+Cabergoline
Meningioma	Patient be subjected to surgery	Use surgical options
	Patient cannot be subjected to surgery	Interferon or Bevacizumab or Hydroxyurea
Glioma	Patient has over expression of MGMT gene	Temozolomide+Radiation or Temozolomide+MGMT-gamma-delta modified Tcells
	Patient does not have over expression of MGMT gene	Temozolomide
AD	Patient needs overall improvement in all AD symptoms	Aducanumab
	Patient needs overall improvements only in memory and thinking functions	Donepezil or Rivastigmine
	Patient needs overall improvements in cognitive functions	Memantine
	Patient needs overall improvement in behavioral functions	Orexin receptor antagonists with suvorexant

Figure 2: Example of NeuroXNet Algorithm for AD Drug Treatment

III. Results and Analysis

3.1 Results for Identification of Blood Biomarkers

Hub Gene	Degree	Clustering Coefficient
CENPF	7	1
DLGAP5	7	0.933333
KIAA0101	7	0.714286
TOP2A	7	0.714286
BUB1B	7	0.666667

Figure 3: Hub Genes for PD

GO Biological Process	Observed Gene Count	Expected Gene Count	Fold Enrichment	P-value	False Discovery Rate
neuron-glia cell signaling (GO:0150099)	3	0.05	58.29	5.62E-05	2.10E-02
positive regulation of heart rate by epinephrine-norepinephrine (GO:0001996)	3	0.06	48.57	8.37E-05	2.63E-02
positive regulation of blood pressure by epinephrine-norepinephrine (GO:0003321)	3	0.07	41.63	1.19E-04	2.96E-02
regulation of systemic arterial blood pressure by norepinephrine-epinephrine (GO:0001993)	3	0.09	32.38	2.14E-04	4.11E-02
GO Molecular Function	Observed Gene Count	Expected Gene Count	Fold Enrichment	P-value	False Discovery Rate
alpha1-adrenergic receptor activity (GO:0004937)	3	0.03	97.15	2.04E-05	1.99E-02
protein domain specific binding (GO:0019904)	21	7.22	2.91	1.66E-05	2.02E-02
GO cellular component	Observed Gene Count	Expected Gene Count	Fold Enrichment	P-value	False Discovery Rate
plasma membrane raft (GO:0044853)	9	1.21	7.41	6.26E-06	1.24E-02
membrane microdomain (GO:0098857)	14	3.5	4	1.74E-05	1.73E-02
membrane raft (GO:0045121)	14	3.5	4	1.74E-05	1.15E-02

Figure 4: Biological, Molecular, and Cellular Functions from PD Over expressed Gene

Five hub genes were found for PD patients with a degree of 7. These genes were CENPF, DLGAP5, KIAA0101, TOP2A, and BUB1B. CENPF or Centromere Protein F is related to the centromere-kinetochore complex and is responsible for chromosome separation during mitosis. The gene is also

differentially expressed in cancer patients. DLG Associated Protein 5 codes for protein and is also found in cancerous patients. DNA Topoisomerase II Alpha (TOP2A) is crucial in the transcription process, helping create enzymes for chromosome segregation and condensation. This gene also counters drug resistance in patients with ataxia-telangiectasia [55].

For the biological function of neuron-glia cell signaling, a fold enrichment value of 58.29 was observed in 3 over-expressed PD genes. In molecular functions, the alpha1-adrenergic receptor activity process had three genes with a fold enrichment of 97.15. This shows that the over-expressed genes are essential biomarkers of PD in patients, and the extremely low false discovery rate supports that this observance is not by random chance.

Gene	Degree	Clustering Coefficient
RPL24	18	0.830065359
RPL31	17	0.911764706
RPL19	17	0.911764706
RPL5	17	0.904411765
RPS16	17	0.882352941
RPL6	17	0.911764706
RPS6	17	0.904411765
RPL36A	17	0.911764706
RPL37A	17	0.904411765

Figure 6: Hub Genes for AD

GO Biological Process	Observed Gene Count	Expected Gene Count	Fold Enrichment	P-value	False Discovery Rate
negative regulation of ubiquitin protein ligase activity (GO:1904667)	3	0.04	80.55	1.21E-05	7.03E-03
regulation of ubiquitin protein ligase activity (GO:1904666)	4	0.07	55.85	1.35E-06	8.17E-04
negative regulation of ubiquitin-protein transferase activity (GO:0051444)	3	0.06	52.36	3.76E-05	1.85E-02
cytoplasmic translation (GO:0002181)	17	0.35	48.64	9.49E-24	1.49E-19
ribosomal large subunit assembly (GO:0000027)	3	0.08	38.79	8.51E-05	3.82E-02
GO Molecular Component	Observed Gene Count	Expected Gene Count	Fold Enrichment	P-value	False Discovery Rate
ubiquitin ligase inhibitor activity (GO:1990948)	3	0.03	> 100	4.78E-06	3.89E-03
ubiquitin-protein transferase inhibitor activity (GO:0055105)	3	0.03	> 100	6.20E-06	4.33E-03
ubiquitin-protein transferase regulator	4	0.07	60.71	1.00E-06	1.22E-03
mRNA 5'-UTR binding (GO:0048027)	4	0.07	53.7	1.56E-06	1.52E-03
GO Cellular Component	Observed Gene Count	Expected Gene Count	Fold Enrichment	P-value	False Discovery Rate
cytosolic large ribosomal subunit (GO:0022625)	11	0.17	66.2	6.19E-17	3.07E-14
polysomal ribosome (GO:0042788)	6	0.09	63.47	1.27E-09	3.15E-07
cytosolic ribosome (GO:0022626)	18	0.3	61	9.38E-27	1.86E-23

Figure 7: Biological, Molecular, and Cellular Functions from AD Over expressed Genes

Gene	Degree	Clustering Coefficient
FYN	7	0.142857143
SNRNP70	5	0.1
CHD4	5	0

Figure 8: Hub Genes for MCI

For MCI patients, three hub genes were found, namely: FYN, SNRNP70, and CHD4. FYN is responsible for cell growth control in the tyrosine kinase protein family. SNRNP70 is responsible for many types of diseases involving body tissue. These hub genes are essential in classifying MCI through blood samples and can serve as a way for neurologists to differentiate between MCI and AD patients because of the different hub genes for each disease.

Gene	Degree	Clustering Coefficient
PRKCA	5	0
CYP7A1	4	0
FZD9	4	0.5
WNT5A	4	0.5
LRP6	4	0.5

Figure 9: Hub Genes for Glioma Tumors

Five hub genes were found for patients with glioma tumors, and two biological processes of calcium ion export and regulation of postsynaptic cytosolic calcium ion concentration had high enrichment values of 38.5 and 35, respectively. PRKCA is associated with other types of cancer.

Gene	Degree	Clustering Coefficient
BICC1	8	0.214285714
MPDZ	7	0.142857143
COL4A2	7	0.333333333
GLI2	7	0.285714286
BTRC	6	0.066666667
PLA2G15	5	0
CTLA4	5	0.1

Figure 10: Pituitary Hub Genes

For patients with pituitary tumors, seven hub genes were found by the model. MPDZ proteins are responsible for HTR2C genes clot in the cell. Together, these hub genes can be used as non-invasive approaches for helping identify pituitary tumors in patients.

Figure 11: Protein Interaction Network for Meningioma Over Expressed Genes

One of the most significant results of the NeuroXNet model was the biomarkers it found for meningioma tumors. The model found 37 hub genes that were overly expressed in patients with meningioma tumors, and all had degrees greater than 64. The model shows that the biological process of DNA replication preinitiation complex assembly has a high enrichment value of 78.31 among the associated hub genes. The cellular function of the cyclin B1-CDK1 complex also has a high enrichment value of 78.31. Some of the hub genes with the highest interactions included CDK1, CCNA2, AURKA, and BUB1 (also associated with PD patients). Cyclin-Dependent Kinase 1 (CDK1) has been associated with breast cancer and is involved in M-phase promoting factors. Cyclin A2 (CCNA2) is also in the same family of genes and is responsible for protein transition. The gene is also found in patients with other types of cancer.

Figure 12: Mean Difference Plot for Meningioma Related Genes

Gene	Degree	Clustering Coefficient
CDK1	82	0.648298705
CCNA2	76	0.746315789
AURKA	76	0.723157895
BUB1	76	0.75122807
CDC20	75	0.76
KIF11	75	0.764324324
CDC45	74	0.759718623
CCNB1	74	0.763791188
ASPM	74	0.778600518
NCAPG	73	0.79718417
CCNB2	72	0.809859155
BIRC5	72	0.780125196
MAD2L1	72	0.781690141
DLGAP5	72	0.8157277
RFC4	72	0.631846635
UBE2C	71	0.805231388
CENPF	71	0.828973843
TPX2	71	0.824144869
MELK	71	0.803219316
PTTG1	71	0.820925553
RACGAP1	70	0.805383023
PRC1	70	0.827329193
MCM2	70	0.776811594
KIF20A	70	0.826915114
NDC80	69	0.825234442
NUSAP1	69	0.859335038
HMMR	69	0.830349531
DTL	69	0.794970162
CEP55	68	0.852941176
RAD51AP1	67	0.857078245
TRIP13	66	0.846153846
CDKN3	66	0.81025641
KIF4A	66	0.854079254
CKS2	66	0.831235431
CENPA	66	0.830769231
MCM6	65	0.808173077
FEN1	65	0.725480769

Figure 13: Meningioma Hub Genes

3.2 NeuroXNet Classification Results

For my sequential model, NeuroXNet, the model starts with a convolutional layer with 32 filters, a stride of 2, the same padding, and a kernel size of 3. The layer takes in the input images using an activation ReLU function. Next, the images are passed into a max-pooling layer with a pool size of 2 and a stride of 2. Then, the images pass through another convolutional layer with filter size 128. Next, the images pass into another max-pooling layer followed by a convolutional layer with filter size 128. Next, the images are passed into a batch normalization layer with a momentum of 0.8. Finally, the images are flattened through a flatten layer and are passed into the dense layer, which uses the softmax function to classify and diagnose the MRI images.

NeuroXNet was created using Keras with a Tensorflow backend and had eight layers. The model has 229,895 total parameters, which is relatively less than previously used models for disease diagnosis. The model architecture is shown below:

It is made available under a [CC-BY-NC 4.0 International license](#).

Model: "sequential"

Layer (type)	Output Shape	Param #
conv2d (Conv2D)	(None, 112, 112, 32)	896
max_pooling2d (MaxPooling2D)	(None, 56, 56, 32)	0
conv2d_1 (Conv2D)	(None, 28, 28, 128)	36992
max_pooling2d_1 (MaxPooling2D)	(None, 14, 14, 128)	0
conv2d_2 (Conv2D)	(None, 7, 7, 128)	147584
batch_normalization (Batch Normalization)	(None, 7, 7, 128)	512
flatten (Flatten)	(None, 6272)	0
dense (Dense)	(None, 7)	43911
Total params: 229,895		
Trainable params: 229,639		
Non-trainable params: 256		

Figure 14: NeuroXNet Model Architecture for Disease Diagnosis

The model had an input of 6300 images from the Training and Validation folders, which is used to train itself. The model was run for 30 epochs and had a training accuracy of 99.79% with a loss of 0.0067 and a validation accuracy of 100% with a 0.0010 loss at the end of the 30 epochs. The training and validation accuracy and loss graphs over the epochs are shown below:

Figure 15: Training and Validation Model Accuracy

Figure 16: Training and Validation Model Loss

Then, the model ran the images on the test set comprising 700 images evenly split into seven classes. The confusion matrix for the testing data is shown below:

Figure 17: Model Confusion Matrix and Heatmap

The confusion matrix shows the number of images in each class and their respective predicted values compared to the actual values from the test set. The confusion matrix also helps visualize the model's performance on the test set through the heatmap colors. The diagonal values of 92, 97, 92, 97, 96, 95, and 94 represent the number of images that NeuroXNet correctly classified in each of the seven classes of AD, MCI, PD, Glioma, Meningioma, Pituitary, and Normal respectively. Out of the 700 images in the test set, NeuroXNet correctly classified 663 pictures, and the rest of the 37 were incorrectly classified. The few incorrect classifications could be caused by the model perceiving features of certain patient MRIs to be similar to multiple diseases making the model rely on a close probability value from the softmax function to diagnose the particular incorrect disease over the correct class. Otherwise, the model performed well, achieving an accuracy of 94.71% for multiclass diagnosis.

Other than the confusion matrix, another way to help see the model's overall performance on the test set is the classification report which gives the precision, recall, f1-score, and support for each of the classes with macro averaging as well as the weighted averaging. The classification report for the model is shown below:

Table 3: Classification Report for Diseases				
	Precision	Recall	F1-score	Support
AD	0.92	0.92	0.92	100
MCI	0.97	0.97	0.97	100
PD	0.92	0.92	0.92	100
Glioma	0.97	0.97	0.97	100
Meningioma	0.96	0.96	0.96	100
Pituitary	0.95	0.95	0.95	100
Normal	0.94	0.94	0.94	100

Table 3: Disease Classification Report

Table 4: Classification Report for Whole Model				
	Precision	Recall	F1-Score	Support
Accuracy			0.95	700
Macro Average	0.95	0.95	0.95	700
Weighted Average	0.95	0.95	0.95	700

Table 4: Model Classification Report

Below are the formulas used in the Classification Report:

$$Precision = \frac{TP}{TP + FP} \text{ (Equation 1)}$$

$$Recall = \frac{TP}{TP + FN} \text{ (Equation 2)}$$

$$F1 = \frac{2 * Precision * Recall}{Precision + Recall} \text{ (Equation 3)}$$

$$Accuracy = \frac{TP + TN}{TP + FN + TN + FP} \text{ (Equation 4)}$$

The precision, recall, and f1-score values for the model are 92%, 97%, 92%, 97%, 96%, 95%, and 94% for AD, MCI, PD, Glioma, Meningioma, Pituitary, and Normal respectively. The accuracy, macro average, and weighted average of all the different methods of calculating performance are 95%, with a support of 700.

In addition, the Cohen's Kappa score for the model was calculated to be 0.9383 with the equation for the score shown below (p_0 represents relating observed agreement and p_c represents the probability of chance agreement):

$$Kappa\ Score = 1 - \frac{1 - p_0}{1 - p_e} \text{ (Equation 5)}$$

The Matthews correlation coefficient was calculated to be 0.9383 with the equation for the coefficient calculation shown below:

$$Coefficient = \frac{TP * TN - FP * FN}{\sqrt{(TP + FP)(TP + FN)(TN + FP)(TN + FN)}} \text{ (Equation 6)}$$

3.3 NeuroXNet Treatment Analysis

After NeuroXNet uses its CNN model to classify neurological diseases correctly, it uses non-imaging data inputted by the radiologist or primary physician to generate treatment recommendations. The algorithmic process that NeuroXNet uses in deciding which treatment to recommend was detailed in section 2. NeuroXNet had a 98% accuracy in predicting treatments plans with the highest survival rates.

In the final analysis, it was observed that the images of the training, validation, and testing sets all attained high accuracies and low loss values, signifying that the NeuroXNet has excellent potential in the diagnosis and treatment of neurological disorders.

IV. Conclusion

This paper helped describe the layers and characteristics of the NeuroXNet model, which achieved a test accuracy of 94.71%. This model is the first CNN model which approaches the diagnosis of neurodegenerative diseases, primarily Alzheimer's disease, Parkinson's disease, and Mild Cognitive Impairment and brain tumors (glioma, meningioma, and pituitary) through a novel deep learning architecture (NeuroXNet). The model helps find new blood biomarkers for the six diseases. Furthermore, NeuroXNet is the first to integrate a treatment component into the model and uses genomic data with the MRI images to diagnose patients. Through this model, doctors and radiologists can diagnose neurological diseases at an earlier stage and use the diagnosis in treating patients with the proper medications and treatment procedures, helping prevent the disease from progressing onto a deadlier stage that could affect the patient's health drastically. Consequently, this model has great potential to be used clinically and improve the lives of numerous patients. Through this paper, a new model is proposed and seen to attain a high accuracy that has many practical applications to radiology, neuroscience, and medicine, helping make a breakthrough in the diagnosis and treatment of neurological diseases using computational and biological approaches.

V. References

- [1] D. Long et al., "Automatic classification of early Parkinson's disease with multi-modal mr imaging", *PLoS ONE*, vol. 7, no. 11, pp. e47714, 2012.
- [2] Soltaninejad, S., Cheng, I., Basu, A.: Towards the identification of Parkinson's disease using only T1 MR images. In: Basu, A., Berretti, S. (eds.) ICSM 2018. LNCS, vol. 11010, pp. 145–156. Springer, Cham (2018).
- [3] Chakraborty S, Aich S, Kim HC. Detection of Parkinson's Disease from 3T T1 Weighted MRI Scans Using 3D Convolutional Neural Network. *Diagnostics (Basel)*. 2020 Jun 12;10(6):402. doi: 10.3390/diagnostics10060402. PMID: 32545609; PMCID: PMC7345307.
- [4] F. E. Al-Khuzai, O. Bayat, and A. D. Duru, "Diagnosis of Alzheimer disease using 2D MRI slices by convolutional neural network," *Applied Bionics and Biomechanics*, vol. 2021.
- [5] Gorji, Hamed Taheri, and Naima Kaabouch. "A Deep Learning approach for Diagnosis of Mild Cognitive Impairment Based on MRI Images." *Brain sciences* vol. 9,9 217. 28 Aug. 2019, doi:10.3390/brainsci9090217.
- [6] Alzheimer's Association. (2021). *2021 ALZHEIMER'S DISEASE FACTS AND FIGURES*. Alzheimer's Association.
- [7] *Statistics*. Parkinson's Foundation. (n.d.). Retrieved September 15, 2021, from <https://www.parkinson.org/Understanding-Parkinsons/Statistics>.
- [8] *Mild cognitive impairment (MCI)*. Alzheimer's Disease and Dementia. (n.d.). Retrieved September 15, 2021, from https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment.
- [9] Hanseeuw, BJ; Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease. *JAMA Neurol* 2019;76(8):915-24. 11.
- [10] <https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055>

- [11] Folego G, Weiler M, Casseb RF, Pires R, Rocha A. Alzheimer's Disease Detection Through Whole-Brain 3D-CNN MRI. *Front Bioeng Biotechnol*. 2020 Oct 30;8:534592. doi: 10.3389/fbioe.2020.534592. PMID: 33195111; PMCID: PMC7661929.
- [12] Saha, Roshni, "Classification of Parkinson's Disease Using MRI Data and Deep Learning Convolution Neural Networks" (2019). Creative Commons. 241.
- [13] Ocasio E, Duong TQ. 2021. Deep learning prediction of mild cognitive impairment conversion to Alzheimer's disease at 3 years after diagnosis using longitudinal and whole-brain 3D MRI. *PeerJ Computer Science* 7:e560 <https://doi.org/10.7717/peerj-cs.560>
- [14] Bhatele K. R, Bhadauria S. S. Classification of Neurodegenerative Diseases Based on VGG 19 Deep Transfer Learning Architecture: A Deep Learning Approach. *Biosc.Biotech.Res.Comm*. 2020;13(4)
- [15] Tong T, Ledig C, Guerrero R, Schuh A, Koikkalainen J, Tolonen A, Rhodius H, Barkhof F, Tijms B, Lemstra AW, Soininen H, Remes AM, Waldemar G, Hasselbalch S, Mecocci P, Baroni M, Lötjönen J, Flier WV, Rueckert D. Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. *Neuroimage Clin*. 2017 Jun 12;15:613-624. doi: 10.1016/j.nicl.2017.06.012. PMID: 28664032; PMCID: PMC5479966.
- [16] Lin CH, Chiu SI, Chen TF, Jang JR, Chiu MJ. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model. *Int J Mol Sci*. 2020 Sep 21;21(18):6914. doi: 10.3390/ijms21186914. PMID: 32967146; PMCID: PMC7555120.
- [17] Gurpreet Singh, Meet Vadera, Lakshminarayanan Samavedham, and Erle Chuen-Hian Lim, *Industrial & Engineering Chemistry Research* **2019** 58 (26), 11498-11505.DOI: 10.1021/acs.iecr.8b06064
- [18] *Role of mris in detecting alzheimer's*. Envision Radiology. (2020, July 21). Retrieved September 15, 2021, from <https://www.envrad.com/role-of-mris-in-detecting-alzheimers/>.
- [19] Fioravanti, V., Benuzzi, F., Codeluppi, L., Contardi, S., Cavallieri, F., Nichelli, P., et al. (2015). MRI correlates of Parkinson's disease progression: a voxel based morphometry study. *Parkinsons Dis*. 2015:378032. doi: 10.1155/2015/378032

- [20] Velazquez, M.; Lee, Y.; Initiative, A.D.N. Random forest model for feature-based Alzheimer's disease conversion prediction from early mild cognitive impairment subjects. *PLoS ONE* 2021, 16, e0244773.
- [21] Irmak, E. Multi-Classification of Brain Tumor MRI Images Using Deep Convolutional Neural Network with Fully Optimized Framework. *Iran J Sci Technol Trans Electr Eng* 45, 1015–1036 (2021). <https://doi.org/10.1007/s40998-021-00426-9> W.-K.
- [22] Sartaj Bhuvaji, Ankita Kadam, Prajakta Bhumkar, Sameer Dedge, and Swati Kanchan, “Brain Tumor Classification (MRI).” Kaggle, 2020, doi: 10.34740/KAGGLE/DSV/1183165.
- [23] Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. *Clin Cancer Res.* 2000 Jul;6(7):2585-97. PMID: 10914698.
- [24] Lee SY. Temozolomide resistance in glioblastoma multiforme. *Genes Dis.* 2016 May 11;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. PMID: 30258889; PMCID: PMC6150109.
- [25] Lamb, L.S., Pereboeva, L., Youngblood, S. *et al.* A combined treatment regimen of MGMT-modified $\gamma\delta$ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. *Sci Rep* 11, 21133 (2021). <https://doi.org/10.1038/s41598-021-00536-8>
- [26] “Brain Tumor Types, Glioblastoma, Meningioma & More.” *Miami Neuroscience Center*, 21 Jan. 2020, <https://miamineurosciencecenter.com/en/conditions/brain-tumors/types/>.
- [27] Silverberg, Gerald. “Brain Shunts Slow Alzheimer's Disease.” *WebMD*, WebMD, 22 Oct. 2002, <https://www.webmd.com/alzheimers/news/20021022/brain-shunts-slow-alzheimers-disease>.
- [28] “Deep Brain Stimulation (DBS).” *Parkinson's Foundation*, <https://www.parkinson.org/Understanding-Parkinsons/Treatment/Surgical-Treatment-Options/Deep-Brain-Stimulation>.
- [29] “Duopa.” *Parkinson's Foundation*, <https://www.parkinson.org/Understanding-Parkinsons/Treatment/Surgical-Treatment-Options/Duopa>.
- [30] H, Cameron M;Lonergan E;Lee. “Transcutaneous Electrical Nerve Stimulation (TENS) for Dementia.” *The Cochrane Database of Systematic Reviews*, U.S. National Library of Medicine, <https://pubmed.ncbi.nlm.nih.gov/12917999/>.

- [31] Kieffer, Sara. "Meningioma Treatment: Johns Hopkins Meningioma Center." *Meningioma Treatment | Johns Hopkins Meningioma Center*, 3 Dec. 2018, <https://www.hopkinsmedicine.org/brain-tumor/specialty-centers/meningioma/treatment.html>.
- [32] "Surgery for Meningioma." *Patient Care at NYU Langone Health*, <https://nyulangone.org/conditions/meningioma/treatments/surgery-for-meningioma>.
- [33] "Alzheimer's Journals: Dementia Journals: Parkinsonism: High Impact Articles: Scient Open Access." *Alzheimer's Journals | Dementia Journals | Parkinsonism | High Impact Articles | Scient Open Access*, <https://scionline.org/archive/23/journal-of-alzheimers-parkinsonism-and-dementia>.
- [34] "Growth Factor Protects Key Brain Cells in Alzheimer's Models." *UCSD News*, https://ucsdnews.ucsd.edu/archive/thisweek/2009/02/16_GrowthFactorAlzheimers.asp.
- [35] "Brain Shunts Slow Alzheimer's Disease." *WebMD*, WebMD, 22 Oct. 2002, <https://www.webmd.com/alzheimers/news/20021022/brain-shunts-slow-alzheimers-disease>.
- [36] "Levodopa and Carbidopa: Medlineplus Drug Information." *MedlinePlus*, U.S. National Library of Medicine, <https://medlineplus.gov/druginfo/meds/a601068.html>.
- [37] Figge DA, Eskow Jaunarajs KL, Standaert DG. Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia. *J Neurosci*. 2016 Jun 15; 36(24):6514-24. doi: 10.1523/JNEUROSCI.0683-16.2016.PMID: 27307239; PMCID: PMC5015786.
- [38] "Medications for Memory, Cognition and Dementia-Related Behaviors." *Alzheimer's Disease and Dementia*, <https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory>.
- [39] "Medication for Meningioma." *Patient Care at NYU Langone Health*, <https://nyulangone.org/conditions/meningioma/treatments/medication-for-meningioma>.
- [40] Kieffer, Sara. "Medication (Drug Therapy): Treatment for Pituitary Tumors: Johns Hopkins Pituitary Tumor Center." *Medication (Drug Therapy) | Treatment for Pituitary Tumors | Johns Hopkins Pituitary Tumor Center*, 5 Oct. 2015, https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/pituitary_center/pituitary-tumor/treatment/drug-therapy.html.

- [41] “Stereotactic Radiosurgery as Effective in Eliminating Parkinson's Disease Tremors as Other Treatments but Less Invasive.” *ScienceDaily*, ScienceDaily, 2 Nov. 2009, <https://www.sciencedaily.com/releases/2009/11/091102121504.htm>.
- [42] Cuttler JM;Abdellah E;Goldberg Y;Al-Shamaa S;Symons SP;Black SE;Freedman M; “Low Doses of Ionizing Radiation as a Treatment for Alzheimer's Disease: A Pilot Study.” *Journal of Alzheimer's Disease : JAD*, U.S. National Library of Medicine, <https://pubmed.ncbi.nlm.nih.gov/33646146/>.
- [43] “Radiation Therapy for Pituitary Tumors.” *American Cancer Society*, <https://www.cancer.org/cancer/pituitary-tumors/treating/radiation-therapy.html>.
- [44] “Meningioma.” *Mayo Clinic*, Mayo Foundation for Medical Education and Research, 21 Apr. 2020, <https://www.mayoclinic.org/diseases-conditions/meningioma/diagnosis-treatment/drc-20355648>.
- [45] “Radiation Therapy for Glioma.” *Memorial Sloan Kettering Cancer Center*, <https://www.mskcc.org/cancer-care/types/glioma/glioma-treatment/radiation-therapy-glioma>.
- [46] Schmidt M, Mock A, Jungk C, Sahm F et al. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. *Oncotarget* 2016 Mar 22;7(12):14551-68. PMID: [26894859](#)
- [47] Dunn J, Lenis VP, Hilton DA, Warta R et al. Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. *Cancers (Basel)* 2020 Nov 5;12(11). PMID: [33167358](#)
- [48] Nilsson RJ, Balaj L, Hulleman E, van Rijn S et al. Blood platelets contain tumor-derived RNA biomarkers. *Blood* 2011 Sep 29;118(13):3680-3. PMID: 21832279
- [49] Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. *Science* 2006 May 26;312(5777):1228-30. PMID: 16728643
- [50] Sood S, Gallagher IJ, Lunnon K, Rullman E et al. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. *Genome Biol* 2015 Sep 7;16:185. PMID: 26343147
- [51] Scherzer CR, Eklund AC, Morse LJ, Liao Z et al. Molecular markers of early Parkinson's disease based on gene expression in blood. *Proc Natl Acad Sci U S A* 2007 Jan 16;104(3):955-60. PMID: 17215369

[52] Scherzer CR, Grass JA, Liao Z, Pepivani I et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 2008 Aug 5;105(31):10907-12. PMID: 18669654

[53] Maes OC, Xu S, Yu B, Chertkow HM et al. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007 Dec;28(12):1795-809. PMID: 16979800

[54] Maes OC, Schipper HM, Chertkow HM, Wang E. Methodology for discovery of Alzheimer's disease blood-based biomarkers. J Gerontol A Biol Sci Med Sci 2009 Jun;64(6):636-45. PMID: 19366883

[55] <https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2A>

[56] Gao, Andrew. Identification of Blood-based Biomarkers for Early Stage Parkinson's Disease. 2020.10.22.20217893; doi: <https://doi.org/10.1101/2020.10.22.20217893>